{"created":"2023-05-15T15:02:51.767382+00:00","id":85191,"links":{},"metadata":{"_buckets":{"deposit":"a17100a2-4769-46dd-8714-035e79d0ec78"},"_deposit":{"created_by":1,"id":"85191","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85191"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085191","sets":["1"]},"author_link":["1042576","1042580","1042582","1042586","1042581","1042585","1042577","1042579","1042578","1042583","1042575","1042584"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"323","bibliographicPageStart":"312","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"Bioactive Materials"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated \nremarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. \nHowever, the efficacy of EGFR-TKIs in wild-type (wt) EGFR tumours has been shown to be marginal. Methods \nthat can sensitize Erlotinib to EGFR wild-type NSCLC remain rare. Herein, we developed a multifunctional \nsuperparamagnetic nanotheranostic agent as a novel strategy to potentiate Erlotinib to EGFR-wt NSCLCs. Our \nresults demonstrate that the nanoparticles can co-escort Erlotinib and a vascular epithermal growth factor \n(VEGF) inhibitor, Bevacizumab (Bev), to EGFR-wt tumours. The nanotheranostic agent exhibits remarkable effects as an inhibitor of EGFR-wt tumour growth. Moreover, Bev normalizes the tumour embedded vessels, further \npromoting the therapeutic efficacy of Erlotinib. In addition, the tumour engagement of the nanoparticles and the \nvascular normalization could be tracked by magnetic resonance imaging (MRI). Collectively, our study, for the \nfirst time, demonstrated that elaborated nanoparticles could be employed as a robust tool to potentiate Erlotinib \nto EGFR-wt NSCLC, paving the way for imaging-guided nanotheranostics for refractory NSCLCs expressing EGFR \nwild-type genes.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"KeAi Publishing"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.bioactmat.2021.10.046","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2452-199X","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Wang, Duo"}],"nameIdentifiers":[{"nameIdentifier":"1042575","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhou, Jun"}],"nameIdentifiers":[{"nameIdentifier":"1042576","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fang, Weimin"}],"nameIdentifiers":[{"nameIdentifier":"1042577","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Huang, Cuiqing"}],"nameIdentifiers":[{"nameIdentifier":"1042578","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chen, Zerong"}],"nameIdentifiers":[{"nameIdentifier":"1042579","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fan, Meng"}],"nameIdentifiers":[{"nameIdentifier":"1042580","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"1042581","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Xiao, Zeyu"}],"nameIdentifiers":[{"nameIdentifier":"1042582","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kuan, Hu"}],"nameIdentifiers":[{"nameIdentifier":"1042583","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Luo, Liangping"}],"nameIdentifiers":[{"nameIdentifier":"1042584","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042585","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kuan, Hu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042586","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A multifunctional nanotheranostic agent potentiates erlotinib to EGFR  wild-type non-small cell lung cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A multifunctional nanotheranostic agent potentiates erlotinib to EGFR  wild-type non-small cell lung cancer"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-22"},"publish_date":"2021-11-22","publish_status":"0","recid":"85191","relation_version_is_last":true,"title":["A multifunctional nanotheranostic agent potentiates erlotinib to EGFR  wild-type non-small cell lung cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:21:36.308311+00:00"}